Literature DB >> 20971270

Treatment of isolated ventricular septal defects in children: Amplatzer versus surgical closure.

Pierre Oses1, Nicolas Hugues, Nagib Dahdah, Suzanne J Vobecky, Joaquim Miro, Michel Pellerin, Nancy C Poirier.   

Abstract

BACKGROUND: Isolated hemodynamically significant ventricular septal defects (VSD) were previously treated surgically. Since the introduction of percutaneous (PC) devices, the management of isolated VSD has evolved. In our center, Amplatzer devices have been implanted for selected isolated perimembranous VSD since 2002.
METHODS: The charts of all isolated PC perimembranous VSD closures and all surgical closures performed since 2002 were reviewed retrospectively. Clinical, electrocardiographic, and echocardiographic data were analyzed. The preclosure, immediate postclosure, and 1-month, 6-month, and 12-month postclosure results were assessed.
RESULTS: Thirty-seven patients underwent PC closure, and 34 had surgical treatment. Mean follow-up was 42.1 ± 26.0 months. The PC group was significantly older (p < 0.01) and larger in size (p < 0.001). Surgical patients had more severe congestive heart failure and a significantly lower VSD gradient (p < 0.004). At follow-up, there were no differences in the incidence of residual shunting between the two groups (p = 0.92). All valvular regurgitations improved over time, except for 3 aortic regurgitations (5.4%) in the PC group that got worse. Two permanent pacemakers were implanted for early complete heart block in the PC group, and one was implanted in the surgical group (p = 0.94).
CONCLUSIONS: The surgical results in our population were excellent. The selection of patients with perimembranous VSD remains a challenge to avoid post-PC intervention complications such as heart block and aortic insufficiency. For isolated VSD, PC closure, which avoids the morbidity of open heart surgery, should be considered as part of the therapeutic armamentarium.
Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20971270     DOI: 10.1016/j.athoracsur.2010.06.088

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Arrhythmias after transcatheter closure of perimembranous ventricular septal defects with a modified double-disk occluder: early and long-term results.

Authors:  Pan Li; Xian-xian Zhao; Xing Zheng; Yong-wen Qin
Journal:  Heart Vessels       Date:  2011-06-04       Impact factor: 2.037

2.  Interventional VSD-Closure with the Nit-Occlud® Lê VSD-Coil in 110 Patients: Early and Midterm Results of the EUREVECO-Registry.

Authors:  Nikolaus A Haas; Laura Kock; Harald Bertram; Regina Boekenkamp; Daniel De Wolf; Igor Ditkivskyy; Matthias W Freund; Marc Gewillig; Christoph M Happel; Ulrike Herberg; Edvard Karthasyan; Rainer Kozlik-Feldmann; Oliver Kretschmar; Yulia Kuzmenko; Ornella Milanesi; Goetz Mueller; Giacomo Pongiglione; Stephan Schubert; Gleb Tarusinov; Christoph Kampmann
Journal:  Pediatr Cardiol       Date:  2016-11-15       Impact factor: 1.655

3.  Comparisons of perventricular device closure, conventional surgical repair, and transcatheter device closure in patients with perimembranous ventricular septal defects: a network meta-analysis.

Authors:  Dongxu Li; Xu Zhou; Mengsi Li; Qi An
Journal:  BMC Surg       Date:  2020-05-26       Impact factor: 2.102

4.  Comparison of transcatheter versus surgical closure of perimembranous ventricular septal defect in pediatric patients: A systematic review and meta-analysis.

Authors:  Sahar El-Kadeem; Shaymaa El Nemr; Doaa El Amrousy; Amr Zoair
Journal:  J Saudi Heart Assoc       Date:  2019-06-25

5.  Key Regulatory Differentially Expressed Genes in the Blood of Atrial Septal Defect Children Treated With Occlusion Devices.

Authors:  Bo-Ning Li; Quan-Dong Tang; Yan-Lian Tan; Liang Yan; Ling Sun; Wei-Bing Guo; Ming-Yang Qian; Allen Chen; Ying-Jun Luo; Zhou-Xia Zheng; Zhi-Wei Zhang; Hong-Ling Jia; Cong Liu
Journal:  Front Genet       Date:  2021-12-08       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.